Effects of nucleus basalis lesion on muscarinic receptor subtypes.
The cholinergic system in the central nervous system is an important component of the neural circuitry of learning, memory and cognition. A decline of cholinergic innervation in the human brain is a characteristic feature of dementia of Alzheimer's type. In this study, changes in cholinergic markers were studied after a unilateral lesion of the nucleus basalis magnocellularis (nbM). Acetylcholinesterase (AChE) histochemistry showed a loss of cortical AChE-containing neurons, and choline acetyltransferase (ChAT) immunohistochemistry demonstrated a loss of cholinergic cells in nbM. The localizations of muscarinic M1 and M2 receptors using [3H]pirenzepine ([3H]PZ) and [3H]AF-DX 384, respectively, were studied by quantitative autoradiography 1, 2, 4 and 6 weeks following unilateral ibotenic acid lesion of nbM. A significant decrease in [3H]PZ binding sites was observed at postlesion week 1 in the parietal and temporal cortices. The decrease in [3H]AF-DX 384 binding sites on the lesioned side was observed throughout frontal, parietal and temporal cortices after postlesion week 1, with a significant increase after 6 weeks, possibly as result of loss of presynaptic receptors and upregulation of postsynaptic ones. Moreover, laminar distribution after nbM lesion shows that M1 and M2 receptor binding sites are more affected in superficial layers (I,II,III) than in the deep layers (IV,V,VI), depending on ligand, postlesion period and cortical region. Furthermore, nbM lesion causes a higher deficit of M2 receptors than of M1 receptors. These data suggest the existence of a presynaptic population as well as a postsynaptic population of M1 and M2 receptors which are differently affected after unilateral nbM lesion.
Bogdanovic
N
N
Department of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.
Islam
A
A
Nilsson
L
L
Bergström
L
L
Winblad
B
B
Adem
A
A
D000110:Acetylcholinesterase / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001345:Autoradiography; D002540:Cerebral Cortex / Q000378:metabolism*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism; D007051:Ibotenic Acid; D007150:Immunohistochemistry; D008297:Male; D009474:Neurons / Q000378:metabolism*; D009847:Olivary Nucleus / Q000502:physiology*; D010276:Parasympatholytics / Q000378:metabolism; D010296:Parietal Lobe / Q000378:metabolism; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000145:classification / Q000378:metabolism*; D013702:Temporal Lobe / Q000378:metabolism; D014316:Tritium
D010276:Parasympatholytics; D011976:Receptors, Muscarinic; D014316:Tritium; C065959:AFDX 384; D007051:Ibotenic Acid; D010890:Pirenzepine; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase